Pharmaceutical - Pharmaceutical, North America, Roche


1 to 25 of 46 results

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead


The 55th American Society of Hematology (ASH) meeting began in New Orleans on Saturday with a host of…

Gilead SciencesNorth AmericaNovartisPharmaceuticalResearchRocheTakeda Pharmaceuticals

US patient share leaders in first-line BRAF-mutation positive malignant melanoma


According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms


Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA


Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

US nephrologists views on prescribing Roche’s Mircera


Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan


The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

FDA advisory panel backs new indication for Genentech's Perjeta


The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Roche/Chugai's bitopertin set to garner $1.5 billion sales in 2022


Swiss drug major Roche (ROG: SIX) and its majority-owned Japanese affiliate Chugai's glycine transporter-1…

AbilifyAbilify MaintenabitopertinChugai PharmaceuticalEuropeGenericsJanssenLundbeckMarkets & MarketingNeurologicalNorth AmericaOtsukaPaliperidonePharmaceuticalRocheSeroquelZyprexa

US and European Rxing decisions on metastatic colorectal cancer


The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads


The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma


US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

US FDA backs news indications for Latuda; grants Priority Review for Perjeta


Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer


For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis


The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Emerging targeted therapies offer advantages over currently-used platinum-resistant ovarian cancer drugs


The effect of an emerging therapy on key efficacy endpoints, including time to disease progression and…

AmgenAstraZenecaAvastinBiotechnologyMarkets & MarketingMerck & CoNorth AmericaolaparibOncologyPharmaceuticalRochetrebananibvintafolide

Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug


The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

US FDA approves Roche's late-stage breast cancer drug Kadcyla


The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Treatment landscape for thyroid carcinoma will change dramatically through 2021; report


Through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the USA and Europe…

BayerdabrafenibEisaiEuropeGlaxoSmithKlinelenvatinibMarkets & MarketingNexavarNorth AmericaOncologyOXiGENEPharmaceuticalRochetrametinibZelborafZybrestat

FDA clears new use for Roche's Avastin and Novartis' Exjade


The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe


For the treatment of hepatitis C virus (HCV), the elimination of interferons (IFNs) from regimens is…

Anti-viralsBiotechnologyEuropeIncivekIncivoJohnson & JohnsonMarkets & MarketingMitsubishi TanabeNorth AmericaPharmaceuticalRocheTelavicVertexVictrelis

FDA Approves Abraxane for NSCLC and expands indication for Actemra


The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising


Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

1 to 25 of 46 results



Back to top